Cancer Research AACR Legacy Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wood, E. R.
Right arrow Articles by Shewchuk, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wood, E. R.
Right arrow Articles by Shewchuk, L.
[Cancer Research 64, 6652-6659, September 15, 2004]
© 2004 American Association for Cancer Research

Regular Articles

A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

Relationships among Protein Conformation, Inhibitor Off-Rate, and Receptor Activity in Tumor Cells

Edgar R. Wood2, Anne T. Truesdale2, Octerloney B. McDonald2, Derek Yuan2, Anne Hassell1, Scott H. Dickerson1, Byron Ellis3, Christopher Pennisi3, Earnest Horne3, Karen Lackey4, Krystal J. Alligood5, David W. Rusnak5, Tona M. Gilmer5 and Lisa Shewchuk1

1 Departments of Computational, Analytical and Structural Sciences, 2 Assay Development and Compound Profiling, 3 Gene Expression and Protein Biochemistry, 4 High-Throughput Chemistry, and 5 Oncology Biology, GlaxoSmithKline, Inc., Research Triangle Park, North Carolina

GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2. We determined the crystal structure of EGFR bound to GW572016. The compound is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously. Surprisingly, we found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa). Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation. We evaluated the duration of the drug effect after washing away free compound and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain. The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells. The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.




This article has been cited by other articles:


Home page
 J Biomol ScreenHome page
C. S. Lebakken, S. M. Riddle, U. Singh, W. J. Frazee, H. C. Eliason, Y. Gao, L. J. Reichling, B. D. Marks, and K. W. Vogel
Development and Applications of a Broad-Coverage, TR-FRET-Based Kinase Binding Assay Platform
J Biomol Screen, September 1, 2009; 14(8): 924 - 935.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
H.-J. Liao and G. Carpenter
Cetuximab/C225-Induced Intracellular Trafficking of Epidermal Growth Factor Receptor
Cancer Res., August 1, 2009; 69(15): 6179 - 6183.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Versele, W. Talloen, C. Rockx, T. Geerts, B. Janssen, T. Lavrijssen, P. King, H. W.H. Gohlmann, M. Page, and T. Perera
Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout
Mol. Cancer Ther., July 1, 2009; 8(7): 1846 - 1855.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
B. Schoeberl, E. A. Pace, J. B. Fitzgerald, B. D. Harms, L. Xu, L. Nie, B. Linggi, A. Kalra, V. Paragas, R. Bukhalid, et al.
Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis
Sci. Signal., June 30, 2009; 2(77): ra31 - ra31.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. S. Yang, Ma. X. G. Ilagan, D. Piwnica-Worms, and L. J. Pike
Luciferase Fragment Complementation Imaging of Conformational Changes in the Epidermal Growth Factor Receptor
J. Biol. Chem., March 20, 2009; 284(12): 7474 - 7482.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
A. Garriz, H. Qiu, M. Dey, E.-J. Seo, T. E. Dever, and A. G. Hinnebusch
A Network of Hydrophobic Residues Impeding Helix {alpha}C Rotation Maintains Latency of Kinase Gcn2, Which Phosphorylates the {alpha} Subunit of Translation Initiation Factor 2
Mol. Cell. Biol., March 15, 2009; 29(6): 1592 - 1607.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Nakagawa, H. Minami, M. Kanezaki, A. Mukaiyama, Y. Minamide, H. Uejima, T. Kurata, T. Nogami, K. Kawada, H. Mukai, et al.
Phase I Dose-escalation and Pharmacokinetic Trial of Lapatinib (GW572016), a Selective Oral Dual Inhibitor of ErbB-1 and -2 Tyrosine Kinases, in Japanese Patients with Solid Tumors
Jpn. J. Clin. Oncol., February 1, 2009; 39(2): 116 - 123.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. Shan, M. A. Seeliger, M. P. Eastwood, F. Frank, H. Xu, M. O Jensen, R. O. Dror, J. Kuriyan, and D. E. Shaw
A conserved protonation-dependent switch controls drug binding in the Abl kinase
PNAS, January 6, 2009; 106(1): 139 - 144.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S.-H. Tan, S.-C. Lee, B.-C. Goh, and J. Wong
Pharmacogenetics in Breast Cancer Therapy
Clin. Cancer Res., December 15, 2008; 14(24): 8027 - 8041.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. F. Press, R. S. Finn, D. Cameron, A. Di Leo, C. E. Geyer, I. E. Villalobos, A. Santiago, R. Guzman, A. Gasparyan, Y. Ma, et al.
HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer
Clin. Cancer Res., December 1, 2008; 14(23): 7861 - 7870.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Bean, G. J. Riely, M. Balak, J. L. Marks, M. Ladanyi, V. A. Miller, and W. Pao
Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma
Clin. Cancer Res., November 15, 2008; 14(22): 7519 - 7525.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. P. Martin, A. Miller, L. Emad, M. Rahmani, T. Walker, C. Mitchell, M. P. Hagan, M. A. Park, A. Yacoub, P. B. Fisher, et al.
Lapatinib Resistance in HCT116 Cells Is Mediated by Elevated MCL-1 Expression and Decreased BAK Activation and Not by ERBB Receptor Kinase Mutation
Mol. Pharmacol., September 1, 2008; 74(3): 807 - 822.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Q. S.C. Chu, M. E. Cianfrocca, L. J. Goldstein, M. Gale, N. Murray, J. Loftiss, N. Arya, K. M. Koch, L. Pandite, R. A. Fleming, et al.
A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer
Clin. Cancer Res., July 15, 2008; 14(14): 4484 - 4490.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. M. Storniolo, M. D. Pegram, B. Overmoyer, P. Silverman, N. W. Peacock, S. F. Jones, J. Loftiss, N. Arya, K. M. Koch, E. Paul, et al.
Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer
J. Clin. Oncol., July 10, 2008; 26(20): 3317 - 3323.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. M. LoRusso, S. F. Jones, K. M. Koch, N. Arya, R. A. Fleming, J. Loftiss, L. Pandite, S. Gadgeel, B. L. Weber, and H. A. Burris III
Phase I and Pharmacokinetic Study of Lapatinib and Docetaxel in Patients With Advanced Cancer
J. Clin. Oncol., June 20, 2008; 26(18): 3051 - 3056.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. J. Burstein, A. M. Storniolo, S. Franco, J. Forster, S. Stein, S. Rubin, V. M. Salazar, and K. L. Blackwell
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer
Ann. Onc., June 1, 2008; 19(6): 1068 - 1074.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Trowe, S. Boukouvala, K. Calkins, R. E. Cutler Jr., R. Fong, R. Funke, S. B. Gendreau, Y. D. Kim, N. Miller, J. R. Woolfrey, et al.
EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation
Clin. Cancer Res., April 15, 2008; 14(8): 2465 - 2475.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Kumar, E. T. Petri, B. Halmos, and T. J. Boggon
Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer
J. Clin. Oncol., April 1, 2008; 26(10): 1742 - 1751.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. R. Wood, L. M. Shewchuk, B. Ellis, P. Brignola, R. L. Brashear, T. R. Caferro, S. H. Dickerson, H. D. Dickson, K. H. Donaldson, M. Gaul, et al.
6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases
PNAS, February 26, 2008; 105(8): 2773 - 2778.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C.-H. Yun, K. E. Mengwasser, A. V. Toms, M. S. Woo, H. Greulich, K.-K. Wong, M. Meyerson, and M. J. Eck
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
PNAS, February 12, 2008; 105(6): 2070 - 2075.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. M. Gilmer, L. Cable, K. Alligood, D. Rusnak, G. Spehar, K. T. Gallagher, E. Woldu, H. L. Carter, A. T. Truesdale, L. Shewchuk, et al.
Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib
Cancer Res., January 15, 2008; 68(2): 571 - 579.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Yu, T. J. Boggon, S. Kobayashi, C. Jin, P. C. Ma, A. Dowlati, J. A. Kern, D. G. Tenen, and B. Halmos
Resistance to an Irreversible Epidermal Growth Factor Receptor (EGFR) Inhibitor in EGFR-Mutant Lung Cancer Reveals Novel Treatment Strategies
Cancer Res., November 1, 2007; 67(21): 10417 - 10427.
[Abstract] [Full Text] [PDF]

Home page
 BioinformaticsHome page
G. M. Verkhivker
Exploring sequence-structure relationships in the tyrosine kinome space: functional classification of the binding specificity mechanisms for cancer therapeutics
Bioinformatics, August 1, 2007; 23(15): 1919 - 1926.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. S. Hegde, D. Rusnak, M. Bertiaux, K. Alligood, J. Strum, R. Gagnon, and T. M. Gilmer
Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles
Mol. Cancer Ther., May 1, 2007; 6(5): 1629 - 1640.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Scaltriti, F. Rojo, A. Ocana, J. Anido, M. Guzman, J. Cortes, S. Di Cosimo, X. Matias-Guiu, S. Ramon y Cajal, J. Arribas, et al.
Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer
J Natl Cancer Inst, April 18, 2007; 99(8): 628 - 638.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. E. Geyer, J. Forster, D. Lindquist, S. Chan, C. G. Romieu, T. Pienkowski, A. Jagiello-Gruszfeld, J. Crown, A. Chan, B. Kaufman, et al.
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
N. Engl. J. Med., December 28, 2006; 355(26): 2733 - 2743.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. Riely, K. A. Politi, V. A. Miller, and W. Pao
Update on Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
Clin. Cancer Res., December 15, 2006; 12(24): 7232 - 7241.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. Moy and P. E. Goss
Lapatinib: Current Status and Future Directions in Breast Cancer
Oncologist, November 1, 2006; 11(10): 1047 - 1057.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. D. Carey, A. J. Garton, M. S. Romero, J. Kahler, S. Thomson, S. Ross, F. Park, J. D. Haley, N. Gibson, and M. X. Sliwkowski
Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib
Cancer Res., August 15, 2006; 66(16): 8163 - 8171.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. E. Konecny, M. D. Pegram, N. Venkatesan, R. Finn, G. Yang, M. Rahmeh, M. Untch, D. W. Rusnak, G. Spehar, R. J. Mullin, et al.
Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells
Cancer Res., February 1, 2006; 66(3): 1630 - 1639.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. H Nelson and C. R Dolder
Lapatinib: A Novel Dual Tyrosine Kinase Inhibitor with Activity in Solid Tumors
Ann. Pharmacother., February 1, 2006; 40(2): 261 - 269.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. A. Burris III, H. I. Hurwitz, E. C. Dees, A. Dowlati, K. L. Blackwell, B. O'Neil, P. K. Marcom, M. J. Ellis, B. Overmoyer, S. F. Jones, et al.
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas
J. Clin. Oncol., August 10, 2005; 23(23): 5305 - 5313.
[Abstract] [Full Text] [PDF]

Home page
 JGPHome page
S. McLaughlin, S. O. Smith, M. J. Hayman, and D. Murray
An Electrostatic Engine Model for Autoinhibition and Activation of the Epidermal Growth Factor Receptor (EGFR/ErbB) Family
J. Gen. Physiol., June 27, 2005; 126(1): 41 - 53.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Liu, S. Majumder, W. McCall, C. I. Sartor, J. L. Mohler, C. W. Gregory, H. S. Earp, and Y. E. Whang
Inhibition of HER-2/neu Kinase Impairs Androgen Receptor Recruitment to the Androgen Responsive Enhancer
Cancer Res., April 15, 2005; 65(8): 3404 - 3409.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Baselga and C. L. Arteaga
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
J. Clin. Oncol., April 10, 2005; 23(11): 2445 - 2459.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
R. A. Mook Jr.
The Importance and Complexities of Target Class Selectivity in Drug Discovery
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 223 - 226.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. R. Burgess, B. J. Skaggs, N. P. Shah, F. Y. Lee, and C. L. Sawyers
Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance
PNAS, March 1, 2005; 102(9): 3395 - 3400.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Brehmer, Z. Greff, K. Godl, S. Blencke, A. Kurtenbach, M. Weber, S. Muller, B. Klebl, M. Cotten, G. Keri, et al.
Cellular Targets of Gefitinib
Cancer Res., January 15, 2005; 65(2): 379 - 382.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.